Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Kappos L, et al. Among authors: dahlke f. Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Lancet. 2018. PMID: 29576505 Clinical Trial.
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH. Molyneux PD, et al. Among authors: dahlke f. Brain. 2000 Nov;123 ( Pt 11):2256-63. doi: 10.1093/brain/123.11.2256. Brain. 2000. PMID: 11050025 Clinical Trial.
Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.
Freeman JA, Thompson AJ, Fitzpatrick R, Hutchinson M, Miltenburger C, Beckmann K, Dahlke F, Kappos L, Polman C, Pozzilli C; European Study Group on Interferon-beta1b in Secondary Progressive MS. Freeman JA, et al. Among authors: dahlke f. Neurology. 2001 Nov 27;57(10):1870-5. doi: 10.1212/wnl.57.10.1870. Neurology. 2001. PMID: 11723278 Clinical Trial.
Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.
Molyneux PD, Barker GJ, Barkhof F, Beckmann K, Dahlke F, Filippi M, Ghazi M, Hahn D, MacManus D, Polman C, Pozzilli C, Kappos L, Thompson AJ, Wagner K, Yousry T, Miller DH; European Study Group on Interferon Beta-1b in Secondary Progressive MS. Molyneux PD, et al. Among authors: dahlke f. Neurology. 2001 Dec 26;57(12):2191-7. doi: 10.1212/wnl.57.12.2191. Neurology. 2001. PMID: 11756596 Clinical Trial.
Can the Expanded Disability Status Scale be assessed by telephone?
Lechner-Scott J, Kappos L, Hofman M, Polman CH, Ronner H, Montalban X, Tintore M, Frontoni M, Buttinelli C, Amato MP, Bartolozzi ML, Versavel M, Dahlke F, Kapp JF, Gibberd R. Lechner-Scott J, et al. Among authors: dahlke f. Mult Scler. 2003 Mar;9(2):154-9. doi: 10.1191/1352458503ms884oa. Mult Scler. 2003. PMID: 12708811
Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.
Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C, McFarland H; European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board. Kappos L, et al. Among authors: dahlke f. Neurology. 2004 Nov 23;63(10):1779-87. doi: 10.1212/01.wnl.0000145561.08973.4f. Neurology. 2004. PMID: 15557490
67 results